Premarket analyst action - healthcare

• Alder Biopharmaceuticals (NASDAQ:ALDR) initiated with Overweight rating and $28 (47% upside) price target at Piper Jaffray.
• Global Blood Therapeutics (NASDAQ:GBT) initiated with Overweight rating and $80 (72% upside) price target at Piper.
• Sage Therapeutics (NASDAQ:SAGE) initiated with Overweight rating and $206 (40% upside) price target at Piper.
• STAAR Surgical (NASDAQ:STAA) reiterated with Buy rating with $45 (18% upside) price target at Benchmark.
• DexCom (NASDAQ:DXCM) upgraded to Buy at Berenberg.
• Intercept Pharmaceuticals (NASDAQ:ICPT) upgraded to Buy with a $157 (62% upside) price target at Goldman Sachs. Shares up 3% premarket.
• HMS Holdings (NASDAQ:HMSY) upgraded to Buy at Citigroup.
• Vital Therapies (NASDAQ:VTL) upgraded to Outperform at William Blair.
• ACADIA Pharmaceuticals (NASDAQ:ACAD) downgraded to Neutral with a $19 (25% upside) price target at Piper. Shares down 3% premarket.
• Horizon Pharma (NASDAQ:HZNP) downgraded to Market Perform with an $18 (flat) price target at BMO.
• Insmed (NASDAQ:INSM) downgraded to Market Perform at JMP Securities.
• Madrigal Pharmaceuticals (NASDAQ:MDGL) downgraded to Neutral with a $314 (25% upside) price target at Goldman.
• Pacira Pharmaceuticals (NASDAQ:PCRX) downgraded to Neutral at BofA/Merrill Lynch.
• TESARO (NASDAQ:TSRO) downgraded to Neutral at BofA/Merrill Lynch. Shares down 1% premarket.